Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JS 207

Next Previous
Drug Profile

JS 207

Alternative Names: JS-207

Latest Information Update: 07 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DotBio
  • Developer Shanghai Junshi Biosciences
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Liver cancer; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 07 Jul 2025 Shanghai Junshi Bioscience plans a phase II trial for Triple-negative Breast Cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease, In adults, In the elderly, First-line therapy or greater) in China (IV) (NCT07045311)
  • 19 Jun 2025 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, In adults, In the elderly, Late-stage disease, Metastatic disease) in China (IV) (NCT06969027)
  • 30 May 2025 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Combination therapy, Second-line therapy or greater, Metastatic disease, Recurrent) in China (Parenteral) (NCT06868836)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top